FDA accepts for priority review application for anti-BCMA CAR T-cell therapy idecabtagene vicleucel (Ide-cel, bb2121)

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA has accepted the Biologics License Application for idecabtagene vicleucel (ide-cel; bb2121) as Priority Review.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login